IDEAYA Biosciences (NASDAQ:IDYA) has released interim data from its ongoing Phase 2 trial of IDE397, a MAT2A inhibitor for MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients.

The data showed a promising 39% overall response rate, including one complete and six partial responses.

The trial, involving 18 heavily pre-treated patients, revealed a disease control rate of 94%, with 14 patients showing tumor shrinkage.

Additionally, the trial demonstrated an excellent safety profile, with only 5.6% experiencing Grade 3 or higher drug-related adverse events.